Clinical Trials Browser

Brain Neoplasms

Colonic Neoplasms

Carcinoma, Renal Cell, Kidney Neoplasms

Breast Neoplasms

Lymphoma, Non-Hodgkin, Multiple Myeloma, Neoplasms

Breast Neoplasms

Breast Neoplasms

Breast Neoplasms

Breast Neoplasms

Breast Neoplasms

Breast Neoplasms

Breast Neoplasms

Breast Neoplasms

Breast Neoplasms

Breast Neoplasms

Breast Neoplasms, Carcinoma, Intraductal, Noninfiltrating

Esophageal Squamour Cell Cancer

Gastrointestinal Stromal Tumors

Endometrial Neoplasms

Liver Neoplasms

Adenocarcinoma, Carcinoma, Non-Small-Cell Lung, Carcinoma, Squamous Cell, Lung Neoplasms

Breast Neoplasms, Carcinoma, Lobular

Breast Neoplasms

Squamous Cell Carcinoma of Head and Neck

Breast Neoplasms, Neoplasm, Residual

Breast Neoplasms

Breast Neoplasms

Breast Neoplasms

ER+ Breast Cancer

Astrocytoma, Oligodendroglioma

Colorectal Neoplasms

Recurrence, Sarcoma, Sarcoma, Ewing

Breast Neoplasms

Breast Neoplasms

Breast Cancer Metastatic

Ovarian Neoplasms

Chordoma, Sarcoma, Osteosarcoma

Breast Neoplasms, Carcinoma, Non-Small-Cell Lung, Gastrointestinal Neoplasms

Breast Neoplasms

Esophageal Squamous Cell Carcinoma

Breast Cancer Female

Breast Neoplasms

Colorectal Neoplasms

Breast Neoplasms

Breast Neoplasms

Clinical Trials

Palbociclib and Pembrolizumab In Central Nervous System Metastases

Palbociclib and Cetuximab in Metastatic Colorectal Cancer

SPARCC

Pembrolizumab, Endocrine Therapy, and Palbociclib in Treating Postmenopausal Patients With Newly Diagnosed Metastatic Stage IV Estrogen Receptor Positive Breast Cancer

TAPUR

PETREMAC

Palbociclib in Combination With Tamoxifen as First Line Therapy for Metastatic Hormone Receptor Positive Breast Cancer

Levels of Circulating Tumor DNA as a Predictive Marker for Early Switch in Treatment for Patients With Metastatic (Stage IV) Breast Cancer

An Exploratory Study of Pertuzumab and Trastuzumab in Combination With Palbociclib and Exemestane as Neoadjuvant Therapy for Triple-Positive Breast Cancer

Clinical Trial Assessing the Safety of Neoadjuvant Palbociclib in Combination With Endocrine Therapy

Combined Immunotherapies in Metastatic ER+ Breast Cancer

Palbociclib With Fulvestrant for Metastatic Breast Cancer After Treatment With Palbociclib and an Aromatase Inhibitor

PD 0332991 and Anastrozole for Stage 2 or 3 Estrogen Receptor Positive and HER2 Negative Breast Cancer

Elacestrant vs Elacestrant Plus a CDK4/6 Inhibitor in Patients With ERpositive/HER2-negative Advanced or Metastatic Breast Cancer

Palbociclib and INCMGA00012 in People With Advanced Liposarcoma

Palbociclib After CDK and Endocrine Therapy (PACE)

WI223281

Neoadjuvant Camrelizumab With Palbociclib for Resectable Esophageal Squamous Cell Carcinoma

CYCLIGIST

Trial of Letrozole + Palbociclib/Placebo in Metastatic Endometrial Cancer

A Clinical Research Study to Determine Whether PD 0332991 May Be Effective in Treating Patients With Liver Cancer

National Lung Matrix Trial: Multi-drug Phase II Trial in Non-Small Cell Lung Cancer

Palbociclib and Endocrine Therapy for LObular Breast Cancer Preoperative Study (PELOPS)

Palbociclib in Combination With Adjuvant Endocrine Therapy for Hormone Receptor Positive, HER2 Negative Invasive Breast Cancer

Los Tres Paso: Neoadjuvant Palbociclib Monotherapy, Concurrent Chemoradiation Therapy, Adjuvant Palbociclib Monotherapy in Patients With p16INK4a Negative, HPV-Unrelated Head and Neck Squamous Cell Carcinoma

PALAVY

ASPIRE

PLATFORM Study of Precision Medicine for Rare Tumors

Aromatase Inhibitor Therapy With or Without Fulvestrant for the Treatment of HR Positive Metastatic Breast Cancer With an ERS1 Activating Mutation, the INTERACT Study

Precision Medicine Trial Based on Molecular Matching Therapy for Patients With Standard Treatment Exhaustion

PARSIFAL

TRAK-ER

Safety and Efficacy of PD0332991 (Palbociclib), a Cyclin-dependent Kinase 4 and 6 Inhibitor, in Patients With Oligodendroglioma or Recurrent Oligoastrocytoma Anaplastic With the Activity of the Protein RB Preserved

SPRING

Binimetinib and Palbociclib or TAS-102 in Treating Patients With KRAS and NRAS Mutant Metastatic or Unresectable Colorectal Cancer

Palbociclib + Ganitumab In Ewing Sarcoma

PATRICIA II

Alternative Dosing Schedule of Palbociclib in Metastatic Hormone Receptor Positive Breast Cancer

PASIPHAE

Palbociclib Plus Letrozole Treatment After Progression to Second Line Chemotherapy for Women With ER/PR-positive Ovarian Cancer

PalboSarc

ROME

PALMIRA

Palbociclib Combined With Afatinib for Advanced Squamous Carcinoma of Esophagus or Gastroesophageal Junction

NeoRHEA

NCT-PMO-1601

ORACLE-RIPA

EVIDENT

Palbociclib and FES PET

BioPER